Cargando…

The Clinical Relevance of the NATALEE Study: Application of the NATALEE Criteria to a Real-World Cohort from Two Large German Breast Cancer Centers

The NATALEE study showed a significant benefit in invasive disease-free survival (iDFS) for patients with HR+/HER2− early breast cancer (eBC) at intermediate and high risk of recurrence who were treated with the CDK4/6 inhibitor Ribociclib in combination with endocrine therapy (ET). This retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schäffler, Henning, Mergel, Franziska, Pfister, Kerstin, Lukac, Stephan, Fink, Angelina, Veselinovic, Kristina, Rack, Brigitte, Fink, Visnja, Leinert, Elena, Dimpfl, Moritz, Englisch, Alexander, Tegeler, Christian Martin, Seller, Anna, Grischke, Eva-Maria, Hahn, Markus, Volmer, Léa Louise, Engler, Tobias, Frevert, Marie Louise, Taran, Florin Andrei, Janni, Wolfgang, Brucker, Sara Yvonne, Hartkopf, Andreas Daniel, Dannehl, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671738/ https://www.ncbi.nlm.nih.gov/pubmed/38003555 http://dx.doi.org/10.3390/ijms242216366

Ejemplares similares

Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer–Real-World Data from Two Large German Breast Centers
por: Dannehl, Dominik, et al.
Publicado: (2023)

Evaluating ChatGPT as an adjunct for the multidisciplinary tumor board decision-making in primary breast cancer cases
por: Lukac, Stefan, et al.
Publicado: (2023)

Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
por: Slamon, Dennis J., et al.
Publicado: (2023)

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
por: Dannehl, Dominik, et al.
Publicado: (2022)

Corrigendum to Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer
Publicado: (2023)

Recurrence Score(®) Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
por: Dannehl, Dominik, et al.
Publicado: (2022)

Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
por: Volmer, Léa L., et al.
Publicado: (2023)

Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer – an Analysis of a Large University Breast Cancer Centre
por: Matovina, Sabine, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
por: Volmer, Léa, et al.
Publicado: (2022)

Human papillomavirus vaccines: A great leap forward
por: Frevert, Marie Louise, et al.
Publicado: (2022)

Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series
por: Walter, Christina, et al.
Publicado: (2020)

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study
por: Herr, Daniel, et al.
Publicado: (2019)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients
por: Volmer, Léa L., et al.
Publicado: (2023)

Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy—results from the prospective multi-center BRENDA II study
por: Leinert, Elena, et al.
Publicado: (2022)

Electrochemotherapy – Supplementary Treatment for Loco-regional Metastasized Breast Carcinoma Administered to Concomitant Systemic Therapy
por: Grischke, Eva-Maria, et al.
Publicado: (2017)

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
por: Kaidun, Polina, et al.
Publicado: (2023)

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients
por: Hartkopf, Andreas D., et al.
Publicado: (2016)

Tumor-Free Resection Margin Distance in the Surgical Treatment of Node-Negative Squamous Cell Cancer of the Vulva Has No Impact on Survival: Analysis of a Large Patient Cohort in a Tertiary Care Center
por: Taran, Florin Andrei, et al.
Publicado: (2023)

A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy
por: Carter, Mary E., et al.
Publicado: (2022)

MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
por: Huebner, Hanna, et al.
Publicado: (2022)

Diabetes duration and the risk of dementia: a cohort study based on German health claims data
por: Reinke, Constantin, et al.
Publicado: (2021)

Ovarian cyst removal influences ovarian reserve dependent on histology, size and type of operation
por: Henes, Melanie, et al.
Publicado: (2018)

Physical activity and cohabitation status moderate the link between diabetes mellitus and cognitive performance in a community-dwelling elderly population in Germany
por: Fink, Anne, et al.
Publicado: (2017)

Advancing Cancer Therapy Predictions with Patient-Derived Organoid Models of Metastatic Breast Cancer
por: Önder, Cansu E., et al.
Publicado: (2023)

Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
por: de Gregorio, Amelie, et al.
Publicado: (2020)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

The volatility of Bitcoin and its role as a medium of exchange and a store of value
por: Baur, Dirk G., et al.
Publicado: (2021)

Peripheral Immune Alterations in Major Depression: The Role of Subtypes and Pathogenetic Characteristics
por: Euteneuer, Frank, et al.
Publicado: (2017)

Immunological effects of behavioral activation with exercise in major depression: an exploratory randomized controlled trial
por: Euteneuer, F, et al.
Publicado: (2017)

Evaluation of sonographic detectability of different markers within an in vitro simulation model of the axilla
por: Guergan, Selin, et al.
Publicado: (2021)

To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis?
por: Herbert, S. L., et al.
Publicado: (2020)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
por: Wöckel, Achim, et al.
Publicado: (2018)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?
por: Polasik, Arkadius, et al.
Publicado: (2017)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

The Long Way From Government Open Data to Mobile Health Apps: Overcoming Institutional Barriers in the US Federal Government
por: Mergel, Ines
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t54kok5idbssca4hl5ta7ncbiv